Abstract

AbstractPurpose: The research on experimental models of primary intraocular lymphoma (PIOL) helps to elucidate pathophysiology of the disease and to find new therapeutical strategies. The purpose of the project was to compare characteristics of two experimental murine models of PIOL.Methods: PIOL was induced in immunocompetent mice by intravitreal injection of syngeneic DLBCL cell suspension. For mice strain C3H/Hen cell line 38C13 was used, for BALB/CaNn it was cell line A20. Following the injection mice were monitored clinically 2 times per week. The experiment was terminated at first signs of exophthalmos or on day 30. Eyes were collected post mortem and histologically processed.Results: Both mice strains show high percentage (above 80%) of PIOL development. Disease progression is faster in C3H/HeN with exophthalmos occurring in all mice no later than day 21, on average on day 11. Vitreous involvement is a predominant sign in the clinical presentation of this group. In BALB/CaNn mice exophthalmos occurs on average on day 22. At the same time, tumorous infiltration of retina, tumorous infiltration of optic disc and tumorous retinal detachment are dominant signs. The difference in development of exophthalmos is most probably due to different affinity of cancer cells for orbital tissue.Conclusions: PIOL has slower progression in BALB/CaNn strain with later or no occurrence of exophthalmos. Varying time of exophthalmos development is most probably due to difference between the affinity of 38C13 and A20 cells for orbital tissue. The primary affinity of the 38C13 cell line for orbital tissue can explain earlier development of exophthalmos in C3H/HeN mice. This and the fact that the PIOL progression is slower in BALB/CaNn strain predisposes the latter to be more suitable for therapeutic experiments planned in the future.Financial support of this project: AZV MZ CR NU20‐03‐00253, SVV UK 260516.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call